5 biomedical technology companies to be acquired in 2017

According to the latest research report of Jefferies, the following five biotech companies are likely to become acquisition targets of bio- or pharmaceutical giants.

1. Bluebird creature

Bluebird Bio (BLUE) is a biotechnology company dedicated to gene therapy. On December 14, 2016, Bluebird announced that it will use the Northstar-2 for the first patient and the LenTIGlobin Phase III clinical trial for patients with blood transfusion-dependent beta-thalassemia (TDT).

Wall Street set its target price at $84.43. Bluebird stock is currently trading at $68.95.

[Inventory] 5 biomedical technology companies to be acquired in 2017

2. Incyte

Incyte (INCY), a pharmaceutical company dedicated to oncology treatment, ranks high on the list of most investors. Recently, investors hope and urge Gilead Science Corporation (GILD) to acquire Incyte. The acquisition of Incyte will boost sales and patent fees for Jakafi's anti-cancer drugs. Last year the drug generated about $1 billion in revenue and is expected to grow further in the future. At the same time, bariciTInib is expected to receive treatment for rheumatoid arthritis in the first quarter of this year, and its patent fees are considerable. In addition, the company has a strong product line.

Wall Street set its target price at $109.58. The Incyte stock is currently trading at $107.17.

3. Medicines Company

The US biopharmaceutical companies Medicines Company (MDCO) and Alnylam Pharmaceuticals (ALNY) announced on November 15, 2016 that the results of the Phase II study of inclisiran in the treatment of hypercholesterolemia in 2016 were optimistic.

The company's cardiovascular, infectious disease and surgical care products are available. In addition to inclisiran, the company also has an anesthetic ABP-700 in the development phase, as well as Carbavance for the treatment of bacterial infections.

The Medicines Company stock is currently trading at $36.02.

4. Kaide Pharmaceutical

Kade Pharmaceuticals (KITE) is a cancer immunotherapy pharmaceutical company. Its flagship product, KTE-C19, is currently undergoing Phase II clinical trials for the treatment of refractory diffuse large B-cell lymphoma, as well as primary mediastinal B-cell lymphoma and transformed follicular lymphoma. On January 3, 2017, Kaide submitted an application for research and development of new drugs (IND) for Kite-718. T cell therapy targeting MAGE A3 and MAGE A6. MAGE A3 and MAGE A6 are frequently found in bladder cancer, esophageal cancer, head and neck cancer, lung cancer and ovarian cancer.

Wall Street set its target price at $75. CapitaLand shares are currently trading at $50.06.

5. Neurocrine Biosciences

Neurocrine Biosciences (NBIX) focuses on the study of the nervous system and endocrine diseases. At present, the company has two main projects that have entered the late stage of research: one is the female drug developed by ABBV (ABBV), the gonadotropin-releasing hormone antagonist elagolix. The second is valbenazine, a monoamine vesicle transporter 2 (VMAT2) inhibitor used to treat dyskinesia.

The company's target price is $68.27. Neurocrine stock is currently trading at $42.66.

24/7 Wall Street contributor Lee Jackson believes, “There is no guarantee that any of these companies will be acquired. But for enterprising investors, there is good news, even if they are not acquired, these stocks are still good. Biotech investment, with a good product line and clear upside potential."

Engine Parts Bolt And Woodruff Key

Woodruff Key,bolt,nut,Engine Parts Bolt And Woodruff Key

Chongqing LDJM Engine Parts Center , https://www.ckcummins.com